학술논문
Anti-C5a Vilobelimab Reduces All-cause Mortality in Critically Ill COVID-19 Patients and in Those With Severe ARDS: A Phase 3 Randomized Double-blind, Placebo-controlled Study
Document Type
Journal
Author
Witzenrath, M.; Vlaar, A. P. J.; Bauer, M.; Annane, D.; Heunks, L.; Mourvillier, B.; Hercilla Vasquez, L.; Welte, T.; van Paassen, P.; de Bruin, S.; Lim, E. H. T.; Brouwer, M. C.; Tuinman, P. R.; Saraiva, J. F.; Marx, G.; Lobo, S. M.; Boldo, R.; Simon-Campos, J.; Cornet, A. D.; Grebenyuk, A.; Engelbrecht, J.; Habel, M.; Thielert, C.; Dickinson, J.; Rueckinger, S.; Zerbib, R.; Neukirchen, D.; Pilz, K.; Guo, R.; van de Beek, D.; Riedemann, N. C.; PANAMO Study Grp
Source
Subject
Language
English
ISSN
15354970